Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Protara Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Protara Therapeutics, Inc.’s stock price such as:

• Protara Therapeutics, Inc.’s current stock price and volume
• Why Protara Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for TARA from analysts
• TARA’s stock price momentum as measured by its relative strength

About Protara Therapeutics, Inc. (TARA)

Before we jump into Protara Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Want to learn more about Protara Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Protara Therapeutics, Inc..

Protara Therapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Protara Therapeutics, Inc.’s stock price was $3.920.

Protara Therapeutics, Inc. is down 2.73% from its previous closing price of $4.030.

During the last market session, Protara Therapeutics, Inc.’s stock traded between $3.805 and $4.040. Currently, there are approximately 57.54 million shares outstanding for Protara Therapeutics, Inc..

Protara Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Protara Therapeutics, Inc. Stock Price History

Protara Therapeutics, Inc.’s (TARA) price is currently up 2.62% so far this month.

During the month of July, Protara Therapeutics, Inc.’s stock price has reached a high of $4.490 and a low of $3.765.

Over the last year, Protara Therapeutics, Inc. has hit prices as high as $7.820 and as low as $2.970. Year to date, Protara Therapeutics, Inc.’s stock is down 26.45%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Protara Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were 0 analysts who downgraded Protara Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Protara Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Protara Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Protara Therapeutics, Inc. (TARA) by visiting AAII Stock Evaluator.

Relative Price Strength of Protara Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Protara Therapeutics, Inc. has a weighted four-quarter relative price strength of 0.81%, which translates to a Momentum Score of 55 and is considered to be Average.

Want to learn more about how Protara Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Protara Therapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Protara Therapeutics, Inc.’s stock price is $3.920, which is down 2.73% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Protara Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.